valproic acid has been researched along with Cardiomyopathies in 4 studies
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.
valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.
Cardiomyopathies: A group of diseases in which the dominant feature is the involvement of the CARDIAC MUSCLE itself. Cardiomyopathies are classified according to their predominant pathophysiological features (DILATED CARDIOMYOPATHY; HYPERTROPHIC CARDIOMYOPATHY; RESTRICTIVE CARDIOMYOPATHY) or their etiological/pathological factors (CARDIOMYOPATHY, ALCOHOLIC; ENDOCARDIAL FIBROELASTOSIS).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Clozapine is the most effective medication for treatment-refractory schizophrenia, but it is associated with severe cardiac adverse events including myocarditis and cardiomyopathy." | 9.22 | Risk factors for clozapine-induced myocarditis and cardiomyopathy: A systematic review and meta-analysis. ( Eriksson, L; Malacova, E; McMahon, K; Moudgil, V; Ramineni, V; Scott, J; Siskind, D; Vickers, M, 2022) |
| "Carnitine deficiency is relatively common in epilepsy; risk factors reportedly include combination antiepileptic drug (AED) therapy with valproic acid (VPA), young age, intellectual disability, diet and enteral or parenteral feeding." | 7.81 | Carnitine deficiency: Risk factors and incidence in children with epilepsy. ( Fukuda, M; Ishii, E; Iwano, S; Kawabe, M; Kikuchi, C; Kuwabara, K; Morimoto, T; Suzuki, Y; Takehara, M; Wakamoto, H, 2015) |
| "Clozapine is the most effective medication for treatment-refractory schizophrenia, but it is associated with severe cardiac adverse events including myocarditis and cardiomyopathy." | 5.22 | Risk factors for clozapine-induced myocarditis and cardiomyopathy: A systematic review and meta-analysis. ( Eriksson, L; Malacova, E; McMahon, K; Moudgil, V; Ramineni, V; Scott, J; Siskind, D; Vickers, M, 2022) |
| "Carnitine deficiency is relatively common in epilepsy; risk factors reportedly include combination antiepileptic drug (AED) therapy with valproic acid (VPA), young age, intellectual disability, diet and enteral or parenteral feeding." | 3.81 | Carnitine deficiency: Risk factors and incidence in children with epilepsy. ( Fukuda, M; Ishii, E; Iwano, S; Kawabe, M; Kikuchi, C; Kuwabara, K; Morimoto, T; Suzuki, Y; Takehara, M; Wakamoto, H, 2015) |
| "VPA is widely used for the treatment of generalized epilepsy." | 2.61 | [Valproic acid-induced hyperammonemic encephalopathy in a patient receiving valproic acid monotherapy]. ( Araki, M; Mukai, T; Naka, H; Shishido, T; Tokinobu, H; Yamada, H, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Vickers, M | 1 |
| Ramineni, V | 1 |
| Malacova, E | 1 |
| Eriksson, L | 1 |
| McMahon, K | 1 |
| Moudgil, V | 1 |
| Scott, J | 1 |
| Siskind, D | 1 |
| Yamada, H | 1 |
| Shishido, T | 1 |
| Mukai, T | 1 |
| Araki, M | 1 |
| Naka, H | 1 |
| Tokinobu, H | 1 |
| Fukuda, M | 1 |
| Kawabe, M | 1 |
| Takehara, M | 1 |
| Iwano, S | 1 |
| Kuwabara, K | 1 |
| Kikuchi, C | 1 |
| Wakamoto, H | 1 |
| Morimoto, T | 1 |
| Suzuki, Y | 1 |
| Ishii, E | 1 |
| Al-sharefi, A | 1 |
| Bilous, R | 1 |
2 reviews available for valproic acid and Cardiomyopathies
| Article | Year |
|---|---|
Risk factors for clozapine-induced myocarditis and cardiomyopathy: A systematic review and meta-analysis.
Topics: Antipsychotic Agents; Cardiomyopathies; Clozapine; Humans; Myocarditis; Risk Factors; Valproic Acid | 2022 |
[Valproic acid-induced hyperammonemic encephalopathy in a patient receiving valproic acid monotherapy].
Topics: Aged; Ammonia; Anticonvulsants; Biomarkers; Cardiomyopathies; Carnitine; Consciousness Disorders; Ep | 2019 |
2 other studies available for valproic acid and Cardiomyopathies
| Article | Year |
|---|---|
Carnitine deficiency: Risk factors and incidence in children with epilepsy.
Topics: Adolescent; Anticonvulsants; Cardiomyopathies; Carnitine; Case-Control Studies; Child; Child, Presch | 2015 |
Reversible weakness and encephalopathy while on long-term valproate treatment due to carnitine deficiency.
Topics: Adult; Antimanic Agents; Brain Diseases; Cardiomyopathies; Carnitine; Female; Humans; Hyperammonemia | 2015 |